GLP-1 Legal Timeline Archive
Complete record of GLP-1 MDL filings, court orders, and key litigation events. Recent items are also summarized on the homepage.
MDL Approaches ~3,000 Cases
Filing pace remains strong; NAION vision-loss claims rising alongside GI allegations.
2,914 Cases Filed
MDL 3094 adds 100+ cases in October, underscoring sustained momentum.
Court Sets 2026 Deadlines
Expert discovery due Mar 27, 2026; summary judgment Apr 16, 2026; bellwethers expected mid-2026.
2,809 Cases on File
September adds 133 cases as filings remain steady.
Lilly Seeks NAION Centralization
Motion to pull all GLP-1 NAION vision-loss suits into MDL 3094 or a parallel MDL.
Court Defines Allowed Claims
MDL permits NAION (optic nerve ischemia) and objectively confirmed gastroparesis claims.
2,676 Cases Filed
Nearly 500 new filings in August alone.
Gastric Emptying Study Requirement
Gastroparesis claimants must provide objective gastric emptying tests or risk exclusion.
Novo Nordisk Sues Compounders
Action against 12 defendants selling compounded semaglutide without FDA approval.
2,190 Cases Filed
Continued growth of MDL 3094 docket.
1,997 Cases Filed
MDL nears 2,000 filings; NAION claims begin to rise.
Study: 24,499 ER Visits
Annals of Internal Medicine links semaglutide to thousands of ER visits in two years.
Severe GI Injury Case
Reported intestinal tissue death and permanent ileostomy after Wegovy/Ozempic use.
Initial Case Centralization
Dozens of early GLP-1 suits centralized in federal court, setting MDL groundwork.